To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.


Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Written Question
Health Services: Waiting Lists
Tuesday 5th December 2023

Asked by: Ben Bradshaw (Labour - Exeter)

Question to the Department of Health and Social Care:

What steps she is taking to reduce NHS waiting times.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

  • Cutting waiting lists is a top priority for this government. We are continuing to work with NHS England to deliver their plan for tackling the backlog and making good progress.

  • We have invested in expanding diagnostic and surgical capacity, creating 135 Community Diagnostics Centres and expanding our surgical hubs to 95 so far, supported by an additional £5.9bn capital investment. This is in addition to £8bn invested in elective recovery through to 2024/25.


Written Question
Evusheld
Tuesday 24th January 2023

Asked by: Ben Bradshaw (Labour - Exeter)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what criteria his Department is using to assess the (a) clinical and (b) cost effectiveness of offering Evusheld on the NHS.

Answered by Will Quince

The Department has asked the National Institute for Health and Care Excellence (NICE) as the independent expert body to develop guidance for the National Health Service on the clinical and cost effectiveness of Evusheld in its licensed indications for the treatment and prevention of COVID-19. NICE will develop guidance in line with its established methods and processes for health technology evaluation which are published and available at the following link:

https://www.nice.org.uk/process/pmg36/chapter/introduction-to-health-technology-evaluation.

NICE is appraising Evusheld for the treatment of COVID-19 alongside other licensed therapeutics and currently expects to publish final guidance in March 2023. NICE’s final guidance on Evusheld for the prevention of COVID-19 is currently expected in April 2023. The NHS in England is legally required to fund medicines recommended by NICE, usually within three months of final guidance.


Written Question
Evusheld
Tuesday 24th January 2023

Asked by: Ben Bradshaw (Labour - Exeter)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when Evusheld will be available on the NHS.

Answered by Will Quince

The Department has asked the National Institute for Health and Care Excellence (NICE) as the independent expert body to develop guidance for the National Health Service on the clinical and cost effectiveness of Evusheld in its licensed indications for the treatment and prevention of COVID-19. NICE will develop guidance in line with its established methods and processes for health technology evaluation which are published and available at the following link:

https://www.nice.org.uk/process/pmg36/chapter/introduction-to-health-technology-evaluation.

NICE is appraising Evusheld for the treatment of COVID-19 alongside other licensed therapeutics and currently expects to publish final guidance in March 2023. NICE’s final guidance on Evusheld for the prevention of COVID-19 is currently expected in April 2023. The NHS in England is legally required to fund medicines recommended by NICE, usually within three months of final guidance.


Written Question
Evusheld
Tuesday 24th January 2023

Asked by: Ben Bradshaw (Labour - Exeter)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what criteria his Department uses to assess the cost-effectiveness of the use of Evusheld against the cost of admission to a hospital for an immune-compromised person with complex health conditions.

Answered by Will Quince

The Department has asked the National Institute for Health and Care Excellence (NICE) as the independent expert body to develop guidance for the National Health Service on the clinical and cost effectiveness of Evusheld in its licensed indications for the treatment and prevention of COVID-19. NICE will develop guidance in line with its established methods and processes for health technology evaluation which are published and available at the following link:

https://www.nice.org.uk/process/pmg36/chapter/introduction-to-health-technology-evaluation.

NICE is appraising Evusheld for the treatment of COVID-19 alongside other licensed therapeutics and currently expects to publish final guidance in March 2023. NICE’s final guidance on Evusheld for the prevention of COVID-19 is currently expected in April 2023. The NHS in England is legally required to fund medicines recommended by NICE, usually within three months of final guidance.


Written Question
Long Covid
Monday 19th December 2022

Asked by: Ben Bradshaw (Labour - Exeter)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many people in the UK have been diagnosed with Long Covid.

Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)

NHS England promotes the use of diagnostic coding for post-COVID-19 syndrome. In primary care, this data is recorded and monitored via OpenSAFELY, which shows as of March 2022, 162,881 people had received a diagnostic code for the long term effects of COVID-19.


Written Question
Chronic Fatigue Syndrome
Monday 19th December 2022

Asked by: Ben Bradshaw (Labour - Exeter)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many people in the UK have been diagnosed with severe Myalgic Encephalomyelitis, as defined in the NICE guidelines.

Answered by Helen Whately - Minister of State (Department of Health and Social Care)

The information requested is not held centrally.


Written Question
Life Expectancy: Exeter
Thursday 10th November 2022

Asked by: Ben Bradshaw (Labour - Exeter)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent assessment she has made of the implications for her policies of trends in the level of life expectancy in Exeter constituency.

Answered by Neil O'Brien

No specific assessment has been made.


Written Question
Surgery: Exeter
Tuesday 8th November 2022

Asked by: Ben Bradshaw (Labour - Exeter)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent estimate her Department has made of the number of cancelled operations in Exeter constituency in the past 12 months.

Answered by Will Quince

This information is not collected in the format requested.


Written Question
Life Expectancy: Exeter
Tuesday 8th November 2022

Asked by: Ben Bradshaw (Labour - Exeter)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment she has made of the implications for her policies of trends in the level of healthy life expectancy in Exeter constituency.

Answered by Neil O'Brien

No specific assessment has been made.


Written Question
HIV Infection: Exeter
Thursday 3rd November 2022

Asked by: Ben Bradshaw (Labour - Exeter)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many people were diagnosed with HIV in Exeter constituency in each of the last 5 five years.

Answered by Neil O'Brien

The information is not collected in the format requested.